Lyon 2020 HFA-ICOS baseline cardiovascular risk before HER2-targeted therapy (trastuzumab and related agents). Very high, high, medium, or low from published factors plus Medium 1/2 points; expert-opinion cardiotoxicity guide <2% / 2-9% / 10-19% / >=20%. Concurrent anthracycline is High; sequential anthracycline before HER2 is Medium 1. Deterministic published classification with citation; not a treatment order. magent does not measure LVEF or biomarkers.

Payment Options